Published in Am J Gastroenterol on September 01, 2003
Hepatocellular carcinoma: A global view. Nat Rev Gastroenterol Hepatol (2010) 5.87
NCCN clinical practice guidelines in oncology: hepatobiliary cancers. J Natl Compr Canc Netw (2009) 3.25
The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis (2010) 2.96
Annual Report to the Nation on the Status of Cancer, 1975-2012, featuring the increasing incidence of liver cancer. Cancer (2016) 2.91
Factors that affect accuracy of α-fetoprotein test in detection of hepatocellular carcinoma in patients with cirrhosis. Clin Gastroenterol Hepatol (2013) 2.30
Index-based dietary patterns and risk of incident hepatocellular carcinoma and mortality from chronic liver disease in a prospective study. Hepatology (2014) 2.14
Association of meat and fat intake with liver disease and hepatocellular carcinoma in the NIH-AARP cohort. J Natl Cancer Inst (2010) 1.81
The epidemiology of hepatocellular cancer: from the perspectives of public health problem to tumor biology. J Gastroenterol (2009) 1.67
National trends and disparities in the incidence of hepatocellular carcinoma, 1998-2003. Prev Chronic Dis (2008) 1.55
Cancer statistics for Asian Americans, Native Hawaiians, and Pacific Islanders, 2016: Converging incidence in males and females. CA Cancer J Clin (2016) 1.53
Racial disparity in primary hepatocellular carcinoma: tumor stage at presentation, surgical treatment and survival. J Natl Med Assoc (2006) 1.52
Detection of hepatocellular carcinoma using glycomic analysis. Clin Cancer Res (2009) 1.52
Characterization of hepatocellular carcinoma related genes and metabolites in human nonalcoholic fatty liver disease. Dig Dis Sci (2013) 1.48
Hepatitis B and hepatocellular carcinoma. Hepatology (2009) 1.44
Seroprevalence of hepatitis C virus and hepatitis B virus among San Francisco injection drug users, 1998 to 2000. Hepatology (2007) 1.40
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat (2013) 1.37
Hepatocellular carcinoma: management of an increasingly common problem. Proc (Bayl Univ Med Cent) (2008) 1.20
Survival differences by race/ethnicity and treatment for localized hepatocellular carcinoma within the United States. Dig Dis Sci (2009) 1.17
Interactions among genes, tumor biology and the environment in cancer health disparities: examining the evidence on a national and global scale. Carcinogenesis (2011) 1.10
Surveillance for hepatocellular carcinoma improves survival in Asian-American patients with hepatitis B: results from a community-based clinic. Dig Dis Sci (2009) 1.09
Immunotherapy of hepatocellular carcinoma: Unique challenges and clinical opportunities. Oncoimmunology (2012) 1.08
HCV-related mortality among male prison inmates in Texas, 1994-2003. Ann Epidemiol (2009) 1.02
Hepatitis C-associated hepatocellular carcinomas in non-cirrhotic livers. Mod Pathol (2009) 0.99
Ethnic differences in hepatocellular carcinoma: implications for liver transplantation. Dig Dis Sci (2007) 0.98
Epidemiology and carcinogenesis of hepatocellular carcinoma. HPB (Oxford) (2005) 0.98
A viral dynamic model for treatment regimens with direct-acting antivirals for chronic hepatitis C infection. PLoS Comput Biol (2012) 0.98
Candidate markers for the detection of hepatocellular carcinoma in low-molecular weight fraction of serum. Carcinogenesis (2007) 0.96
Recent developments in the first detection of hepatocellular carcinoma. Clin Biochem Rev (2005) 0.93
Clinical presentation of hepatocellular carcinoma (HCC) in Asian-Americans versus non-Asian-Americans. J Immigr Minor Health (2011) 0.93
Treatment of hepatitis C virus infection in the future. Clin Transl Med (2013) 0.93
Genetic variation in CLDN1 and susceptibility to hepatitis C virus infection. J Viral Hepat (2009) 0.88
Clinical presentation and survival of Asian and non-Asian patients with HCV-related hepatocellular carcinoma. Dig Dis Sci (2013) 0.87
HCV NS5A abrogates p53 protein function by interfering with p53-DNA binding. World J Gastroenterol (2004) 0.86
Problem of hepatocellular carcinoma in West Africa. World J Hepatol (2014) 0.86
Circulating microRNA-122a as a diagnostic marker for hepatocellular carcinoma. Onco Targets Ther (2013) 0.85
Reliability and validity of a self-efficacy instrument for hepatitis C antiviral treatment regimens. J Viral Hepat (2011) 0.83
Alpha fetoprotein DNA prime and adenovirus boost immunization of two hepatocellular cancer patients. J Transl Med (2014) 0.81
Social support and clinical outcomes during antiviral therapy for chronic hepatitis C. J Psychosom Res (2011) 0.80
Less-established risk factors are common in Asian Americans with hepatitis C virus: a case-controlled study. Dig Dis Sci (2013) 0.80
Critical reappraisal of risk factors for occurrence of hepatocellular carcinoma in patients with hepatitis C virus. Hepat Med (2011) 0.78
Molecular Signatures of Recurrent Hepatocellular Carcinoma Secondary to Hepatitis C Virus following Liver Transplantation. J Transplant (2013) 0.78
Assessment of hepatitis C risk factors and infection prevalence in a jail population. Am J Public Health (2014) 0.78
Role of hepatitis C virus induced osteopontin in epithelial to mesenchymal transition, migration and invasion of hepatocytes. PLoS One (2014) 0.78
Comparative diagnostic efficacy of serum squamous cell carcinoma antigen in hepatocellular carcinoma. BMC Res Notes (2012) 0.77
Survival of patients with hepatocellular carcinoma in the San Joaquin Valley: a comparison with California Cancer Registry data. Ann Gastroenterol (2012) 0.77
Genes transactivated by hepatitis C virus core protein, a microarray assay. World J Gastroenterol (2005) 0.77
The CD133+CD44+ precancerous subpopulation of oval cells is a therapeutic target for hepatocellular carcinoma. Stem Cells Dev (2014) 0.77
Viral hepatitis markers in liver tissue in relation to serostatus in hepatocellular carcinoma. Cancer Epidemiol Biomarkers Prev (2013) 0.77
Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine (Baltimore) (2017) 0.75
Tumor factors associated with clinical outcomes in patients with hepatitis B virus infection and hepatocellular carcinoma. Gastroenterol Hepatol (N Y) (2012) 0.75
Higher Glucose and Insulin Levels Are Associated with Risk of Liver Cancer and Chronic Liver Disease Mortality among Men without a History of Diabetes. Cancer Prev Res (Phila) (2016) 0.75
Integrating recent data in managing adverse events in the treatment of hepatocellular carcinoma. Gastroenterol Hepatol (N Y) (2010) 0.75
Liver Transplantation for Hepatocellular Carcinoma among African Americans in the United States. Int J Organ Transplant Med (2012) 0.75
Risk Factors and Treatment for Hepatocellular Carcinoma. Gastroenterol Hepatol (N Y) (2006) 0.75
Ambovex(®) as a novel immunological modulator drug for the treatment of hepatocellular carcinoma (HCC) in the liver: a Phase II clinical trial. J Hepatocell Carcinoma (2015) 0.75
IL6 gene allele-specific C/EBPα-binding activity affects the development of HBV infection through modulation of Th17/Treg balance. Genes Immun (2015) 0.75
Prognostic factors of hepatocellular carcinoma survival after radiofrequency ablation: A US population-based study. United European Gastroenterol J (2016) 0.75
Association of serum vitamin B12 levels with stage of liver fibrosis and treatment outcome in patients with chronic hepatitis C virus genotype 1 infection: a retrospective study. BMC Res Notes (2015) 0.75
Increased sialylation of site specific O-glycoforms of hemopexin in liver disease. Clin Proteomics (2016) 0.75
Regulation of the metastasis suppressor Nm23-H1 by tumor viruses. Naunyn Schmiedebergs Arch Pharmacol (2014) 0.75
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report. Biol Blood Marrow Transplant (2005) 19.83
Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med (2013) 13.30
Genome-wide association study of CNVs in 16,000 cases of eight common diseases and 3,000 shared controls. Nature (2010) 12.27
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Telaprevir for retreatment of HCV infection. N Engl J Med (2011) 10.48
Genome-wide association study meta-analysis identifies seven new rheumatoid arthritis risk loci. Nat Genet (2010) 9.90
Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med (2014) 9.25
Gene expression in fixed tissues and outcome in hepatocellular carcinoma. N Engl J Med (2008) 9.20
The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology (2012) 5.47
Resection of hepatocellular cancer ≤2 cm: results from two Western centers. Hepatology (2013) 5.05
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med (2014) 4.90
hORFeome v3.1: a resource of human open reading frames representing over 10,000 human genes. Genomics (2007) 4.62
Resection and liver transplantation for hepatocellular carcinoma. Semin Liver Dis (2005) 4.51
Alpha-fetoprotein, des-gamma carboxyprothrombin, and lectin-bound alpha-fetoprotein in early hepatocellular carcinoma. Gastroenterology (2009) 4.50
High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis. Nat Genet (2012) 4.46
Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. Cancer Res (2008) 4.35
Differentiation of the major Listeria monocytogenes serovars by multiplex PCR. J Clin Microbiol (2004) 4.32
Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C. N Engl J Med (2009) 4.21
Measuring therapeutic response in chronic graft-versus-host disease: National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IV. Response Criteria Working Group report. Biol Blood Marrow Transplant (2006) 4.09
Wound healing recapitulates morphogenesis in Drosophila embryos. Nat Cell Biol (2002) 4.04
Pivotal role of mTOR signaling in hepatocellular carcinoma. Gastroenterology (2008) 4.03
Genome-wide molecular profiles of HCV-induced dysplasia and hepatocellular carcinoma. Hepatology (2007) 3.85
Genetic variants at CD28, PRDM1 and CD2/CD58 are associated with rheumatoid arthritis risk. Nat Genet (2009) 3.52
Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood (2002) 3.45
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med (2014) 3.40
Management of hepatitis B: summary of a clinical research workshop. Hepatology (2007) 3.40
Outcome of sustained virological responders with histologically advanced chronic hepatitis C. Hepatology (2010) 3.35
Nonalcoholic fatty liver disease: diagnostic and fat-grading accuracy of low-flip-angle multiecho gradient-recalled-echo MR imaging at 1.5 T. Radiology (2009) 3.31
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial. Lancet Infect Dis (2013) 3.30
The novel role of tyrosine kinase inhibitor in the reversal of immune suppression and modulation of tumor microenvironment for immune-based cancer therapies. Cancer Res (2009) 3.18
Public health impact of antiviral therapy for hepatitis C in the United States. Hepatology (2009) 3.10
Live imaging of innate immune cell sensing of transformed cells in zebrafish larvae: parallels between tumor initiation and wound inflammation. PLoS Biol (2010) 2.99
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: 2008 update. Clin Gastroenterol Hepatol (2008) 2.97
Adefovir dipivoxil alone or in combination with lamivudine in patients with lamivudine-resistant chronic hepatitis B. Gastroenterology (2004) 2.97
Randomized study comparing banding and propranolol to prevent initial variceal hemorrhage in cirrhotics with high-risk esophageal varices. Gastroenterology (2005) 2.90
New staging system and a registry for perihilar cholangiocarcinoma. Hepatology (2011) 2.89
Quantitative serum HBV DNA levels during different stages of chronic hepatitis B infection. Hepatology (2002) 2.79
High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis. Hepatology (2009) 2.75
A randomized, prospective, double-blind, placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome. Gastroenterology (2008) 2.69
Treatment alternatives for chronic hepatitis B virus infection: a cost-effectiveness analysis. Ann Intern Med (2005) 2.68
Effect of treatment with peginterferon or interferon alfa-2b and ribavirin on steatosis in patients infected with hepatitis C. Hepatology (2003) 2.66
Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol (2008) 2.66
Serum alpha-fetoprotein levels in patients with advanced hepatitis C: results from the HALT-C Trial. J Hepatol (2005) 2.63
Dense genotyping of immune-related disease regions identifies 14 new susceptibility loci for juvenile idiopathic arthritis. Nat Genet (2013) 2.60
c-Jun regulates eyelid closure and skin tumor development through EGFR signaling. Dev Cell (2003) 2.59
The role of social scientists in synthetic biology. Science & Society Series on Convergence Research. EMBO Rep (2009) 2.57
Long-term outcomes of positive fluorescence in situ hybridization tests in primary sclerosing cholangitis. Hepatology (2010) 2.55
Wound repair at a glance. J Cell Sci (2009) 2.53
Hepatocellular carcinoma: consensus recommendations of the National Cancer Institute Clinical Trials Planning Meeting. J Clin Oncol (2010) 2.51
Herbal product use by persons enrolled in the hepatitis C Antiviral Long-Term Treatment Against Cirrhosis (HALT-C) Trial. Hepatology (2008) 2.44
Ras pathway activation in hepatocellular carcinoma and anti-tumoral effect of combined sorafenib and rapamycin in vivo. J Hepatol (2009) 2.42
Gene-expression signature of vascular invasion in hepatocellular carcinoma. J Hepatol (2011) 2.39
High-dose ursodeoxycholic acid is associated with the development of colorectal neoplasia in patients with ulcerative colitis and primary sclerosing cholangitis. Am J Gastroenterol (2011) 2.38
Live imaging of wound inflammation in Drosophila embryos reveals key roles for small GTPases during in vivo cell migration. J Cell Biol (2005) 2.38
Persistence and adherence to nucleos(t)ide analogue treatment for chronic hepatitis B. J Hepatol (2010) 2.38
Hepatitis B virus genotypes in the United States: results of a nationwide study. Gastroenterology (2003) 2.38
Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared with hepatitis B virus genotype C. Gastroenterology (2002) 2.34
A molecular signature to discriminate dysplastic nodules from early hepatocellular carcinoma in HCV cirrhosis. Gastroenterology (2006) 2.32
New aspects regarding evolution and virulence of Listeria monocytogenes revealed by comparative genomics and DNA arrays. Infect Immun (2004) 2.31
Frequent inactivation of the tumor suppressor Kruppel-like factor 6 (KLF6) in hepatocellular carcinoma. Hepatology (2004) 2.29
Epoetin alfa maintains ribavirin dose in HCV-infected patients: a prospective, double-blind, randomized controlled study. Gastroenterology (2004) 2.28
Adefovir-resistant hepatitis B can be associated with viral rebound and hepatic decompensation. J Hepatol (2005) 2.26
Effect of lamivudine treatment on survival of 309 North American patients awaiting liver transplantation for chronic hepatitis B. Liver Transpl (2002) 2.25
Entecavir for treatment of lamivudine-refractory, HBeAg-positive chronic hepatitis B. Gastroenterology (2006) 2.22
The impact of race/ethnicity on the clinical epidemiology of autoimmune hepatitis. J Clin Gastroenterol (2012) 2.20
An explicit quality indicator set for measurement of quality of care in patients with cirrhosis. Clin Gastroenterol Hepatol (2010) 2.18
Predictors of response to terlipressin plus albumin in hepatorenal syndrome (HRS) type 1: relationship of serum creatinine to hemodynamics. J Hepatol (2010) 2.16
Monoclonal antibody HCV-AbXTL68 in patients undergoing liver transplantation for HCV: results of a phase 2 randomized study. Liver Transpl (2006) 2.12
Kidney transplantation alone in ESRD patients with hepatitis C cirrhosis. Transplantation (2012) 2.10
Hepatitis B virus genotypes: do they play a role in the outcome of HBV infection? Hepatology (2004) 2.09
A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology (2005) 2.08
Commentary: Gastroenterology and hepatology: an evolving marriage, not an imminent divorce. Am J Gastroenterol (2009) 2.08
Noninvasive monitoring of patients with chronic hepatitis C. Hepatology (2002) 2.08
Dynamic analysis of dorsal closure in Drosophila: from genetics to cell biology. Dev Cell (2002) 2.06
Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology (2006) 2.06
Sustained virologic response rates with telaprevir by response after 4 weeks of lead-in therapy in patients with prior treatment failure. J Hepatol (2012) 2.05
Virologic response and resistance to adefovir in patients with chronic hepatitis B. J Hepatol (2005) 2.04
Treatment of hepatitis C after kidney transplant: a pooled analysis of observational studies. J Med Virol (2014) 2.03
Dynamic analysis of filopodial interactions during the zippering phase of Drosophila dorsal closure. Development (2008) 2.03
Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results. Hepatology (2009) 2.02
Molecular mechanisms linking wound inflammation and fibrosis: knockdown of osteopontin leads to rapid repair and reduced scarring. J Exp Med (2008) 1.99
Virological breakthrough and resistance in patients with chronic hepatitis B receiving nucleos(t)ide analogues in clinical practice. Hepatology (2011) 1.98
Downregulation of KLF6 is an early event in hepatocarcinogenesis, and stimulates proliferation while reducing differentiation. J Hepatol (2006) 1.98
Peginterferon alfa-2a for hepatitis C after liver transplantation: two randomized, controlled trials. Hepatology (2005) 1.97
6-thioguanine can cause serious liver injury in inflammatory bowel disease patients. Gastroenterology (2003) 1.95
Impact of the model for end-stage liver disease allocation policy on the use of high-risk organs for liver transplantation. Gastroenterology (2008) 1.95
Wound healing and inflammation: embryos reveal the way to perfect repair. Philos Trans R Soc Lond B Biol Sci (2004) 1.94
A treatment algorithm for the management of chronic hepatitis B virus infection in the United States: an update. Clin Gastroenterol Hepatol (2006) 1.92
Evaluation for liver transplantation in adults: 2013 practice guideline by the American Association for the Study of Liver Diseases and the American Society of Transplantation. Hepatology (2014) 1.91
HBV genotype B is associated with better response to interferon therapy in HBeAg(+) chronic hepatitis than genotype C. Hepatology (2002) 1.88
Recent US Food and Drug Administration warnings on hepatitis B reactivation with immune-suppressing and anticancer drugs: just the tip of the iceberg? Hepatology (2015) 1.87
Toward biomarkers for chronic graft-versus-host disease: National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: III. Biomarker Working Group Report. Biol Blood Marrow Transplant (2006) 1.86
Blood and marrow transplant clinical trials network toxicity committee consensus summary: thrombotic microangiopathy after hematopoietic stem cell transplantation. Biol Blood Marrow Transplant (2005) 1.85
Overlapping genetic susceptibility variants between three autoimmune disorders: rheumatoid arthritis, type 1 diabetes and coeliac disease. Arthritis Res Ther (2010) 1.85